Literature DB >> 28883220

A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission.

Yasunobu Sekiguchi1, Mutsumi Wakabayashi1, Haruko Takizawa1, Keiji Sugimoto1, Shigeki Tomita2, Hiroshi Izumi2, Noriko Nakamura3, Tomohiro Sawada3, Yasunori Ohta4, Norio Komatsu5, Masaaki Noguchi1.   

Abstract

Entities:  

Keywords:  Waldenstrom Macroglobulinemia; bendamustine; hepatitis B carrier; intermittent administration; one-day administration

Mesh：

Substances：

Year:  2017        PMID： 28883220      PMCID： PMC6158059          DOI： 10.3960/jslrt.17022

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN： 1346-4280


× No keyword cloud information.
  10 in total

1.  Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Authors:  Michinori Ogura; Toshiki Uchida; Masafumi Taniwaki; Kiyoshi Ando; Takashi Watanabe; Masanobu Kasai; Yosuke Matsumoto; Daisuke Shimizu; Yoshiaki Ogawa; Ken Ohmachi; Hiroki Yokoyama; Kensei Tobinai
Journal:  Cancer Sci       Date:  2010-09       Impact factor: 6.716

2.  Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.

Authors:  R Kath; K Blumenstengel; H J Fricke; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2001-01       Impact factor: 4.553

3.  Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.

Authors:  Joel S Owen; Murad Melhem; Julie A Passarell; Denise D'Andrea; Mona Darwish; Bradley Kahl
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-06       Impact factor: 3.333

4.  Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Authors:  Liang-Tsai Hsiao; Hwei-Fang Tien; Ching-Yuan Kuo; Jin-Hou Wu; Hsin-An Hou; Ming-Chung Wang; Chun-Yu Liu; Po-Min Chen; Tzeon-Jye Chiou
Journal:  Hematol Oncol       Date:  2014-08-11       Impact factor: 5.271

5.  Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

Authors:  Michinori Ogura; Kiyoshi Ando; Masafumi Taniwaki; Takashi Watanabe; Toshiki Uchida; Ken Ohmachi; Yosuke Matsumoto; Kensei Tobinai
Journal:  Cancer Sci       Date:  2011-07-07       Impact factor: 6.716

Review 6.  Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.

Authors:  Bruce D Cheson; Clemens-Martin Wendtner; Angelika Pieper; Martin Dreyling; Jonathan Friedberg; Dieter Hoelzer; Philippe Moreau; John Gribben; Stefan Knop; Marco Montillo; Mathias Rummel
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-02

7.  Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

Authors:  Brad S Kahl; Nancy L Bartlett; John P Leonard; Ling Chen; Kristen Ganjoo; Michael E Williams; Myron S Czuczman; K Sue Robinson; Robin Joyce; Richard H van der Jagt; Bruce D Cheson
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

8.  Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.

Authors:  Mona Darwish; Gail Megason; Mary Bond; Edward Hellriegel; Philmore Robertson; Thaddeus Grasela; Luann Phillips
Journal:  Curr Med Res Opin       Date:  2014-08-11       Impact factor: 2.580

9.  A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.

Authors:  Marika Rasschaert; Dirk Schrijvers; Jan Van den Brande; Joke Dyck; Johan Bosmans; Karlheinz Merkle; Jan B Vermorken
Journal:  Anticancer Drugs       Date:  2007-06       Impact factor: 2.248

Review 10.  Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.

Authors:  Mona Darwish; Mary Bond; Edward Hellriegel; Philmore Robertson; James P Chovan
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-01       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.